TRAIL R2-specific multimeric scaffolds
US9212231B2 · kind B2 · utility
1Cited by
5References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2011 |
| Grant date | Dec 15, 2015 |
| Priority date | — |
| Expiry date | May 8, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.